College of Pharmacy, The Ohio State University, Columbus, OH.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Blood Adv. 2021 Jan 12;5(1):66-70. doi: 10.1182/bloodadvances.2020003366.
Pre-HCT mosaicism is related to increased relapse risk and lower survival after unrelated HCT, independent of cytogenetics at diagnosis. Pre-HCT mosaicism could be a useful clinical tool to guide risk stratification in acute lymphoblastic leukemia patients.
预处理 HCT 嵌合体与无关 HCT 后复发风险增加和生存率降低有关,与诊断时的细胞遗传学无关。预处理 HCT 嵌合体可能是指导急性淋巴细胞白血病患者风险分层的有用临床工具。